We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

efgartigimod

Advertisement

cGxPJobs Banner

argenx Reports Long-Term Efgartigimod Benefits in Myositis and Sjogren’s Disease at EULAR 2026

AMSTERDAM, Netherlands, June 3, 2026 argenx presented new clinical data at the European Alliance of Associations for Rheumatology (EULAR)...

By cGxPwire Editor
June 5, 2026

Read More

Argenx Gains FDA Approval Expanding VYVGART to All gMG Patients

AMSTERDAM, Netherlands, May 8, 2026 Argenx SE announced that the U.S. Food and Drug Administration (FDA) has approved a...

By cGxPwire Editor
May 11, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

Bio-Pharma

Agilent Expands FDA-Approved PD-L1 Testing for KEYTRUDA Across Four Cancer Types
June 5, 2026
02

Bio-Pharma

Zenas BioPharma Reports Positive Phase 3 Obexelimab Results in IgG4-RD
June 5, 2026
03

Bio-Pharma

DBV Technologies Screens First Infant in THRIVE Peanut Allergy Study
June 5, 2026
04

.Clinical

argenx Reports Long-Term Efgartigimod Benefits in Myositis and Sjogren’s Disease at EULAR 2026
June 5, 2026
05

.Clinical

Levicept’s LEVI-04 Shows Disease-Modifying Potential in Osteoarthritis
June 5, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website